I have always been deeply skeptical of these hodgepodge baskets of fringe stocks. Sitting here in 2026, these are the companies desperately trying to carve out a sliver of relevance while Big Tech eats the rest of the world. They span consumer goods, industrials, healthcare, and crypto derivatives. The only thing they have in common? They aren't the household names making headlines every day. But that doesn't mean they aren't worth dissecting. The truth is, while the giants are feasting, these players are fighting tooth and nail for the scraps.

Let's start with the thrill-seekers trying to monetize chaos. ProShares Ultra VIX Short-Term Futures (EUVX.US) is still playing its old game, capitalizing on the fear of S&P 500 volatility. It has seen some wild swings recently. Honestly, it's just a game of chicken for day traders. Meanwhile, X-BET MAGNETICS (XBTY.US) is even more absurd. This fund is out here combining put-writing strategies with leveraged Bitcoin exposure. It saw a brief rally recently that some are calling a bullish signal. Good luck with that. It's essentially playing Russian roulette in a Vegas casino.

On the flip side, the hard assets and traditional income plays are less insane, though aggressively boring. GraniteShares Platinum Trust (PLTM.US) recently saw its NAV surge thanks to a bump in platinum prices, but let's not ignore the fact that it posted a net loss of USD 7 million for fiscal year 2026. PIMCO New York Municipal Income Fund (PNF.US), on the other hand, continues to serve as a tax-haven incubator for wealthy New Yorkers, even as its operating income dropped 16.3% last quarter.

The physical retail and consumer space is where things actually get interesting. Steven Madden (SHOO.US) just dropped a surprisingly solid Q2 2026 earnings report, with revenue up over 19% to USD 665.9 million, prompting an upward revision in full-year guidance. In this retail environment, that is actually doing the work. Jack in the Box (JACK.US) is not so lucky. The burger chain just appointed a new president, Taylor Montgomery, presumably to fix the ongoing slide in Q3 system-wide sales. Why aren't you moving faster on product innovation? Shuffling executives doesn't fix a fundamentally broken menu.

In tech and industrials, it's a tale of two extremes. Inseego (INSG.US) is going through a painful reality check. Despite a Q2 revenue beat, product delays and a slow FWA recovery tanked its stock post-market, forcing a guidance cut. Regal Rexnord (RRX.US), however, is crushing it. Q2 GAAP net income skyrocketed 46.7%. New CEO Aamir Paul seems to have perfectly positioned the company to supply data centers and robotics. That is how you actually capitalize on a trend instead of just talking about it.

Finally, let's look at healthcare. The Cooper Companies (COO.US) remains a quiet juggernaut in contact lenses and women's health, recently raising its fiscal 2026 revenue guidance to over USD 4.3 billion. And then there is Zhongchao Inc. (ZDAI.US). The cancer-care platform just executed a 1-for-3 reverse stock split and issued new shares to raise a measly USD 5 million. This is stupid and here's why: doing financial gymnastics just to keep your listing alive is not a business model. The days of zero-revenue healthcare platforms telling fairy tales are over in 2026.

This article does not constitute investment advice.